Full Analysis
Clinical Trial
Does semaglutide reduce heart attacks and strokes in people with obesity but no diabetes?
Original title: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun +13 moreNew England Journal of Medicine2023-11-11DOI
Sample Size
17 participants
Study Type
Clinical Trial
Duration
Mean duration of exposure 34.2±13.7 months; mean follow-up 39.8±9.4 months
Overview
In Plain Language
Weekly semaglutide injections reduced heart attacks, strokes, and cardiovascular deaths by 20% in people with obesity and heart disease but no diabetes.
Clinical trial17 participants
The Numbers
Absolute risk: 6.5% in semaglutide group vs 8.0% in placebo group (absolute risk reduction of 1.5 percentage points)
Relative risk (Hazard ratio; absolute):
- Hazard ratio 0.80